Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 47

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

Journal Articles

Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Elias Jabbour, Nicholas Short, Nitin Jain, Partow Kebriaei, Richard E Champlin, Issa F. Khouri, Elizabeth J Shpall, Patrice Nasnas, Aram Bidikian, Rebecca Garris, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 3155–3157.

https://doi.org/10.1182/blood-2022-171189

Published: 2022

Journal Articles

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

Blood (2022) 140 (Supplement 1): 8973–8975.

https://doi.org/10.1182/blood-2022-157323

Published: 2022

Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Blood (2022) 140 (Supplement 1): 8966–8968.

https://doi.org/10.1182/blood-2022-157358

Published: 2022

Journal Articles

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Tareq Abuasab, Srdan Verstovsek, Gautam Borthakur, Rashmi Kanagal-Shamanna, Keyur Patel, Koichi Takahashi, Lucia Masarova, Prithviraj Bose, John Villarreal, Sherry A. Pierce, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Nicholas Short, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 8954–8956.

https://doi.org/10.1182/blood-2022-165455

Published: 2022

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6170–6172.

https://doi.org/10.1182/blood-2022-164986

Published: 2022

Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 4042–4044.

https://doi.org/10.1182/blood-2022-170029

Published: 2022

Journal Articles

Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

Blood (2022) 140 (Supplement 1): 7725–7728.

https://doi.org/10.1182/blood-2022-169896

Published: 2022

Journal Articles

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Fadi Haddad, Georgio Medawar, Rashmi Kanagal-Shamanna, Hector Alvarez, Sanam Loghavi, Naval Daver, Sherry A. Pierce, Elias Jabbour, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Hussein A Abbas, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 3196–3198.

https://doi.org/10.1182/blood-2022-169991

Published: 2022

Journal Articles

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

Oren Pasvolsky, Rima M. Saliba, Celina Ledesma, Uday R Popat, Amin M Alousi, Amanda L. Olson, Betul Oran, Chitra Hosing, Qaiser Bashir, Muzaffar H Qazilbash, Nicholas Short, Farhad Ravandi, Richard E Champlin, Elizabeth J Shpall, Partow Kebriaei

Blood (2022) 140 (Supplement 1): 7695–7696.

https://doi.org/10.1182/blood-2022-155916

Published: 2022

Journal Articles

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Nitin Jain, Farhad Ravandi, Tharakeswara K. Bathala, Aram Bidikian, Fadi Haddad, Patrice Nasnas, Naval Daver, Tapan M. Kadia, Rebecca Garris, Monica Kwari, Hagop Kantarjian, Elias Jabbour

Blood (2022) 140 (Supplement 1): 3182–3184.

https://doi.org/10.1182/blood-2022-170931

Published: 2022

Journal Articles

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9078–9079.

https://doi.org/10.1182/blood-2022-167349

Published: 2022

Journal Articles

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2022) 140 (Supplement 1): 9050–9053.

https://doi.org/10.1182/blood-2022-171011

Published: 2022

Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Blood (2022) 140 (Supplement 1): 9041–9043.

https://doi.org/10.1182/blood-2022-168029

Published: 2022

Journal Articles

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Faustine Ong, Nicholas Short, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Musa Yilmaz, Yesid Alvarado, Kenneth Vaughan, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9029–9031.

https://doi.org/10.1182/blood-2022-159110

Published: 2022

Journal Articles

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Blood (2022) 140 (Supplement 1): 6064–6066.

https://doi.org/10.1182/blood-2022-170458

Published: 2022

Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood (2022) 140 (Supplement 1): 11698–11701.

https://doi.org/10.1182/blood-2022-170049

Published: 2022

Journal Articles

A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes

Blood (2022) 140 (Supplement 1): 11679–11682.

https://doi.org/10.1182/blood-2022-168052

Published: 2022

Journal Articles

Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL)

Rodrick Babakhanlou, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Marina Konopleva, William G. Wierda, Jan A. Burger, Ghayas C. Issa, Abhishek Maiti, Hayley Balkin, Mary Kelly, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia-Manero, Yesid Alvarado, Nicholas Short, Nitin Jain, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 11671–11673.

https://doi.org/10.1182/blood-2022-159139

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes

Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only